Black patients with ES-SCLC get less chemo, CTCs may guide breast cancer treatment, and new FDA approvals for neuroblastoma and prostate cancer

Blood & Cancer news stories:

1. Black patients with ES-SCLC get less chemo but have better survival: https://bit.ly/33Rb5eB
2. Should CTCs guide treatment choice in HR+, HER2– breast cancer?: https://bit.ly/3gn6shc
3. New drug approved for relapsed/refractory neuroblastoma: https://bit.ly/2VMpvIy
4. FDA approves first agent for PSMA-PET imaging in prostate cancer: https://bit.ly/36TAaY7

Contact Blood & Cancer at podcasts@mdedge.com.